HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy-Reference-Cited by-同舟云学术

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

Published:2018-03-29 Issue:5 Volume:218 Page:688-697
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Wijting Ingeborg E A¹,Lungu Cynthia²,Rijnders Bart J A¹,van der Ende Marchina E¹,Pham Hanh T³⁴,Mesplede Thibault³⁴,Pas Suzan D²,Voermans Jolanda J C²,Schuurman Rob⁵,van de Vijver David A M C²,Boers Patrick H M²,Gruters Rob A²,Boucher Charles A B²,van Kampen Jeroen J A²

Affiliation:

1. Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands

2. Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands

3. McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada

4. Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montreal, Canada

5. Division of Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/218/5/688/25206918/jiy176.pdf

Reference45 articles.

1. Quantitative evaluation of the antiretroviral efficacy of dolutegravir;Laskey;JCI Insight,2016

2. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance;Brenner;Virus Res,2017

3. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial;Walmsley;J Acquir Immune Defic Syndr,2015

4. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO;Molina;J Int AIDS Soc,2014

5. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial;Raffi;Lancet Infect Dis,2013

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review;2024-01-07

2. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review;Viruses;2023-09-15

3. Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6;The Journal of Infectious Diseases;2023-07-27

4. Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania;Open Forum Infectious Diseases;2023-06-26

5. HIV-1 3′-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles;Journal of Virology;2023-05-31